References

1. de Wit D, Guchelaar H-J, den Hartigh J, Gelderblom H, van Erp NP. Individualized dosing of tyrosine kinase inhibitors: are we there yet?Drug Discov Today . 2015;20(1):18-36. doi:10.1016/j.drudis.2014.09.007
2. Widmer N, Bardin C, Chatelut E, et al. Review of therapeutic drug monitoring of anticancer drugs part two–targeted therapies. Eur J Cancer . 2014;50(12):2020-2036. doi:10.1016/j.ejca.2014.04.015
3. Klümpen H-J, Samer CF, Mathijssen RHJ, Schellens JHM, Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors.Cancer Treat Rev . 2011;37(4):251-260. doi:10.1016/j.ctrv.2010.08.006
4. Yu H, Steeghs N, Nijenhuis CM, Schellens JHM, Beijnen JH, Huitema ADR. Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets.Clin Pharmacokinet . 2014;53(4):305-325. doi:10.1007/s40262-014-0137-2
5. Janssen JM, Dorlo TPCC, Steeghs N, et al. Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. Clin Pharmacol Ther . 2020;0(0):cpt.1808. doi:10.1002/cpt.1808
6. Riggs MM, Cremers S. Pharmacometrics and systems pharmacology for metabolic bone diseases. Br J Clin Pharmacol . 2019;85(6):1136-1146. doi:10.1111/bcp.13881
7. Huang S-M, Abernethy DR, Wang Y, Zhao P, Zineh I. The utility of modeling and simulation in drug development and regulatory review.J Pharm Sci . 2013;102(9):2912-2923. doi:10.1002/jps.23570
8. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol . 2004;22(5):935-942. doi:10.1200/JCO.2004.03.050
9. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res . 2009;15(12):4220-4227. doi:10.1158/1078-0432.CCR-08-2740
10. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol . 2006;24(1):25-35. doi:10.1200/JCO.2005.02.2194
11. Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit . 2009;31(5):579-584. doi:10.1097/FTD.0b013e3181b2c8cf
12. Aspeslet LJ, LeGatt DF, Murphy G, Yatscoff RW. Effect of assay methodology on pharmacokinetic differences between cyclosporine Neoral and Sandimmune formulations. Clin Chem . 1997;43(1):104-108. http://www.ncbi.nlm.nih.gov/pubmed/8990230.
13. Scholten EM, Cremers SCLM, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int . 2005;67(6):2440-2447. doi:10.1111/j.1523-1755.2005.00352.x
14. Chatelut E, Bruno R, Ratain MJ. Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors. Clin Pharmacol Ther . 2018;103(6):956-958. doi:10.1002/cpt.937
15. FDA. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics. Published 2018. Accessed April 1, 2020.
16. Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clin Pharmacokinet . 2017;56(9):987-997. doi:10.1007/s40262-017-0510-z
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer . 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026
18. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol . 2012;30(34):4249-4255. doi:10.1200/JCO.2012.42.5967
19. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed March 31, 2020.
20. Atkinson TM, Ryan SJ, Bennett A V., et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer . 2016;24(8):3669-3676. doi:10.1007/s00520-016-3297-9
21. Ferner R, Aronson J. Susceptibility to adverse drug reactions.Br J Clin Pharmacol . 2019;85(10):2205-2212. doi:10.1111/bcp.14015
22. Dancey JE, Dobbin KK, Groshen S, et al. Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents. Clin Cancer Res . 2010;16(6):1745-1755. doi:10.1158/1078-0432.CCR-09-2167
23. KKGT (Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie). Oral oncolytics. http://kkgt.nl/?page_id=3661&lang=en. Accessed March 31, 2020.
24. Gotta V, Widmer N, Decosterd LA, et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.Cancer Chemother Pharmacol . 2014;74(6):1307-1319. doi:10.1007/s00280-014-2599-1
25. Gotta V, Bouchet S, Widmer N, et al. Large-scale imatinib dose–concentration–effect study in CML patients under routine care conditions. Leuk Res . 2014;38(7):764-772. doi:10.1016/j.leukres.2014.03.023
26. Kloprogge F, Simpson JA, Day NPJ, White NJ, Tarning J. Statistical power calculations for mixed pharmacokinetic study designs using a population approach. AAPS J . 2014;16(5):1110-1118. doi:10.1208/s12248-014-9641-4
27. Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat . 2009;8(1):38-49. doi:10.1002/pst.326
28. Demetri GD, Wang Y, Wehrle E, et al. Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors. J Clin Oncol . 2009;27(19):3141-3147. doi:10.1200/JCO.2008.20.4818
29. Guilhot F, Hughes TP, Cortes J, et al. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica . 2012;97(5):731-738. doi:10.3324/haematol.2011.045666
30. Suttle AB, Ball HA, Molimard M, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer . 2014;111(10):1909-1916. doi:10.1038/bjc.2014.503
31. Amengual JE, Johannet P, Lombardo M, et al. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clin Cancer Res . 2015;21(20):4663-4675. doi:10.1158/1078-0432.CCR-14-3068
32. Westerdijk K, Desar IME, Steeghs N, Graaf WTA, Erp NP. Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol . 2020;86(2):258-273. doi:10.1111/bcp.14185
33. Groenland SL, van Eerden RAG, Verheijen RB, et al. Therapeutic Drug Monitoring of Oral Anticancer Drugs. Ther Drug Monit . 2019;41(5):561-567. doi:10.1097/FTD.0000000000000654
34. de Wit D, van Erp NP, den Hartigh J, et al. Therapeutic Drug Monitoring to Individualize the Dosing of Pazopanib. Ther Drug Monit . 2015;37(3):331-338. doi:10.1097/FTD.0000000000000141
35. Lankheet NAG, Desar IME, Mulder SF, et al. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol . 2017;83(10):2195-2204. doi:10.1111/bcp.13327
36. Rousselot P, Johnson-Ansah H, Huguet F, et al. Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study. Blood . 2015;126(23):133 LP - 133. http://www.bloodjournal.org/content/126/23/133.abstract.
37. Lankheet NAG, Knapen LM, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care. Ther Drug Monit . 2014;36(3):326-334. doi:10.1097/FTD.0000000000000004
38. S Bouchet, P Rousselot, F Guilhot, J Guilhot, A Guerci, F Nicolini, A Charbonnier, FX Mahon MM. Abstract CO-038 of the 19th Annual Meeting of French Society of Pharmacology and Therapeutics, 36th Pharmacovigilance Meeting, 16th APNET Seminar, 13th CHU CIC Meeting 21–23 April 2015 Caen, France. Fundam Clin Pharmacol . 2015;29(6):9-10. doi:10.1111/fcp.12104
39. Zuidema S, Desar IME, Erp NP, Kievit W. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study. Br J Clin Pharmacol . 2019;85(9):1994-2001. doi:10.1111/bcp.13990
40. Ribba B, Dudal S, Lavé T, Peck RW. Model‐Informed Artificial Intelligence: Reinforcement Learning for Precision Dosing. Clin Pharmacol Ther . 2020;107(4):853-857. doi:10.1002/cpt.1777